An Open-Label, Long-Term Follow Up Study of Safety and Efficacy in PKU Subjects with PAH Deficiency Previously Administered HMI 102
Phenylketonuria, PAH Deficiency
Enrolling by invitation
This Long-Term Follow Up Study will evaluate the safety and efficacy of PKU Subjects with PAH Deficiency Previously Administered HMI 102. Subjects will have already received a single dose of HMI-102 administered intravenously
Subject was previously administered HMI 102.
Subject is able to understand the purpose and risks of the study and is willing to provide informed consent.
Subject is able to comply with all study procedures and long-term follow-up.
Participation in the study is not in the subject's best interest, in the opinion of the Investigator.
June 30, 2022
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
For more information and to contact the study team: